Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (referred to as "AgeX" in the text, though the request metadata lists "Serina Therapeutics, Inc.") on March 18, 2019. The company is incorporated in Delaware and is headquartered in Alameda, California. The filing reports on the exercise of common stock purchase warrants.
Key Financial Metrics
- Cash Inflow: AgeX received $4,500,000 from the exercise of warrants.
- Shares Issued: 1,800,000 shares of common stock were issued.
- Exercise Price: $2.50 per share.
- Revenue, Profit, Margins, Debt: The filing text does not provide a clear value for these metrics as this is a transaction-specific report, not a periodic financial statement.
Material Changes
The primary material change reported is the increase in outstanding common stock by 1,800,000 shares and the corresponding increase in cash assets due to the warrant exercises. The filing notes that any warrants not exercised by the reporting date have expired.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors detailed in other SEC filings. No specific operational guidance or new risk contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the company name discrepancy between the request metadata ("Serina Therapeutics") and the filing text ("AgeX Therapeutics").
- Confirm the total number of shares outstanding post-transaction.
- Review the company's cash position to assess the impact of the $4.5 million inflow on liquidity.
- Check subsequent filings to ensure no further warrant exercises or expirations occurred after March 18, 2019.